Highlights

  • Dimerix entered an exclusive licensing agreement with Everest Medicines covering Greater China, South Korea and Southeast Asia for DMX-200.
  • The agreement includes potential milestone payments of up to approximately A$481 million plus tiered royalties on net sales.
  • Dimerix will receive a US$10 million upfront payment under the agreement, subject to completion conditions.
  • The company’s ACTION3 Phase 3 trial for DMX-200 is fully recruited with 333 patients across 21 countries.

Dimerix (ASX:DXB) has secured its fifth licensing agreement for lead drug candidate DMX-200, granting Everest Medicines exclusive rights across Greater China, South Korea and Southeast Asia in a deal with potential value of up to approximately A$481 million plus royalties.

Announced on 16 June 2026, the agreement expands Dimerix's regional Partnership network for its focal segmental glomerulosclerosis (FSGS) treatment candidate without requiring the company to establish its own commercial infrastructure across these markets.

The transaction provides near-term non-dilutive funding through an upfront payment while DMX-200 continues through its pivotal Phase 3 development program.

What Was Announced?

Dimerix announced an exclusive licensing agreement with Everest Medicines covering mainland China, Hong Kong, Macao, Taiwan, South Korea and six Southeast Asian countries including Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines.

Under the agreement, Dimerix will receive a US$10 million upfront payment, equivalent to approximately A$14.1 million, within 45 Business days of execution.

The deal also includes up to US$30 million in development and regulatory milestones and up to US$300 million in commercial milestones, bringing the total potential value to approximately A$481 million.

In addition, Dimerix is eligible to receive tiered royalties of 10–15% on net sales across licensed territories.

DMX-200 is a small molecule targeting the CCR2 chemokine receptor, which plays a role in inflammatory pathways. The therapy is being developed alongside standard angiotensin II receptor blocker treatment for patients with FSGS, a rare kidney disease that can progress to kidney failure.

DMX-200 holds Orphan Drug Designations in the United States, Europe, the United Kingdom and Japan. Patent protection currently extends to 2032, with pending applications that could potentially extend protection to 2042.

Why This Matters

For Dimerix (ASX:DXB), licensing agreements provide a pathway to commercialise DMX-200 internationally without building regulatory, sales and distribution infrastructure across multiple regions.

The Everest Medicines agreement expands access to several Asian pharmaceutical markets while providing a near-term upfront payment ahead of the ACTION3 Phase 3 trial outcome.

The headline potential value of approximately A$481 million represents the maximum possible consideration under the agreement. Most of this amount depends on future regulatory approvals, commercial milestones and sales performance, meaning the majority of payments are not guaranteed.

The agreement also represents additional external interest in DMX-200 while the company continues to advance its pivotal clinical program.

Company Background

Dimerix (ASX:DXB) is an ASX-listed clinical-stage biopharmaceutical company focused on DMX-200 for FSGS, alongside earlier-stage pipeline Assets developed through acquisitions.

FSGS is a kidney disease characterised by scarring of the kidney filters and can progress to kidney failure. Dimerix has estimated that the condition affects hundreds of thousands of patients across the territories now licensed to Everest Medicines.

The company’s commercial strategy has focused on regional licensing partnerships while retaining responsibility for funding and conducting the global ACTION3 Phase 3 trial.

Previous DMX-200 licensing agreements include partnerships with Advanz Pharma, Taiba Rare, Fuso Pharmaceutical Industries and Amicus Therapeutics/BioMarin.

Financial Position

Dimerix reported approximately A$26.6 million in cash and cash equivalents at the end of its most recent quarterly reporting period, compared with approximately A$38.5 million in the previous quarter.

The reduction reflected net operating cash use of around A$11.5 million, primarily associated with ACTION3 trial activities, patient recruitment completion and Manufacturing requirements.

The company has previously disclosed receiving more than A$65 million from its first four DMX-200 licensing agreements combined.

Dimerix has also flagged a proposed non-dilutive funding Facility of up to US$50 million, approximately A$70 million, which remains subject to finalisation.

What Comes Next?

The immediate financial milestone for Dimerix (ASX:DXB) is receipt of the US$10 million upfront payment from Everest Medicines, expected within 45 business days of agreement execution.

The key clinical milestone remains the ACTION3 Phase 3 trial readout. The study is fully recruited with 333 adult patients across 21 countries.

An interim analysis in 2024 showed DMX-200 outperforming placebo on proteinuria reduction, while a blinded statistical review in April 2026 confirmed the trial retained more than 90% statistical power for its primary endpoint.

The company has also completed eight independent Data Monitoring Committee safety reviews without concerns raised.

Risks

Dimerix (ASX:DXB) remains dependent on successful completion of the ACTION3 Phase 3 trial and regulatory approval of DMX-200. The majority of the Everest Medicines agreement value is linked to future development, regulatory and commercial milestones that may not be achieved. Although interim trial assessments have supported the study design, Phase 3 outcomes remain uncertain. The company continues to use cash to fund clinical obligations, while the proposed funding facility has not yet been finalised.

Investor Takeaway

The Everest Medicines agreement expands Dimerix’s DMX-200 commercial network into major Asian markets and provides a potential funding source ahead of the Phase 3 trial outcome.

The approximately A$481 million headline value represents a maximum potential amount rather than confirmed revenue, with most payments dependent on future milestones and commercial performance.

For Dimerix (ASX:DXB), the next major Factor remains the ACTION3 Phase 3 readout. The trial’s completion, safety reviews and statistical assessments provide ongoing visibility, but final efficacy results will determine whether DMX-200 can progress toward regulatory approval and commercialisation.